The Cocktail Report (sound really smart around your friends):
George Church's team at Harvard's Wyss Institute trained a computer model to tell a cell's age from which genes are active.
They used it to screen genes in old human skin cells, and the top hit was SRSF1, a protein that edits gene messages.
SRSF1 made old cells look younger without turning them into stem cells or changing what kind of cell they were.
Old mice given the gene through a liver-seeking virus grew frail 44% more slowly than controls.
Treated mice lived 14% longer at the median, and frailty set in about 123 days later.
If you are past 60, frailty is likely a bigger worry than any birthday number: weaker legs, slower walks and more falls. A new mouse study from Harvard puts a single gene on the short list of things that slowed that slide.
The paper appeared October 14 in Nature Aging from George Church's lab at the Wyss Institute and Harvard Medical School, working with a team in Spain. The full paper is behind a paywall, so this report draws on the abstract, figure notes, and two Harvard releases.
How the gene was found
The team first built a transcriptomic age predictor, a computer model that estimates a cell's age from which genes are switched on and how strongly. They trained it on fibroblasts, the skin cells that build the skin's support tissue, from donors across a wide age range.
Next, they turned up candidate genes in old fibroblasts and asked the model which ones made the cells score younger. The winner was SRSF1, a splicing factor, meaning a protein that edits a gene's message before the cell turns it into a protein.
What it did in a dish
In old cells, extra SRSF1 cut back three features of aging. Fewer cells became senescent (stopped dividing but refused to die), protein handling improved, and inflammatory signaling dropped.
The cells also stayed fibroblasts. The better-known Yamanaka factors, a set of genes that can push cells back toward a stem-cell state, raise worries about toxicity, and SRSF1 did not switch on those stem-cell programs.
What it did in old mice
The team loaded the mouse version of the gene into an adeno-associated virus (AAV), a disabled virus used to carry genes, chosen because it travels to the liver. Most of the gene did end up in the liver.
Treated mice grew frail 44% more slowly than control mice, and their median lifespan was 14% longer. Sustained frailty began about 123 days later in the treated group.
Church said his lab's long-standing goal is finding genes that, when tuned in target tissues, "extend human health span".
What this means for you
You have likely been told that rejuvenation research runs almost entirely through the Yamanaka factors. This study points to another route: one ordinary editing protein, already present in every cell, that made old cells score younger while leaving their identity in place.
There is nothing to take or ask your doctor for. SRSF1 is a research target, delivered here by gene therapy in mice, and no human treatment exists.
What this study does and does not show
To be frank, the lifespan result rests on 10 treated mice and 9 controls, and the authors describe the lifespan gain as "associated with" the treatment. Only 6 treated mice and 4 controls reached the frailty cutoff behind the 123-day figure.
Not every tissue benefited: muscle fiber size did not improve when SRSF1 was given by a different virus. Several authors are named on a patent covering SRSF1, and Church and first author Alexandru Plesa co-founded RegulaBio, a company developing aging therapies.
Why Should You Care?
Frailty, more than any single disease, is what takes independence away from many older adults. A gene that slowed frailty in old mice is a lead worth following, even if it is years from any clinic.
Plesa AM, Jung S, Wang HH, et al., Church GM. "Transcriptomic reprogramming screen identifies SRSF1 as a regulator of aging." Nature Aging. Published October 14, 2026. DOI: 10.1038/s43587-026-01234-8. https://link.springer.com/article/10.1038/s43587-026-01234-8
Wyss Institute for Biologically Inspired Engineering at Harvard University. "Reversing age by reprogramming gene expression networks." October 14, 2026. https://wyss.harvard.edu/news/reversing-age-by-reprogramming-gene-expression-networks/
Harvard Medical School. "New Screening Platform Helps Identify Genes With Tissue-Rejuvenation Potential." October 15, 2026. https://hms.harvard.edu/news/new-screening-platform-helps-identify-genes-tissue-rejuvenation-potential
